Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149:1226–39.

Article  CAS  PubMed  Google Scholar 

Xue W, Wang XW. The search for precision models clinically relevant to human liver cancer. Hepat Oncol. 2015;2:315–9.

Article  PubMed  PubMed Central  Google Scholar 

Roberts AJ, Kon T, Knight PJ, Sutoh K, Burgess SA. Functions and mechanics of dynein motor proteins. Nat Rev Mol Cell Biol. 2013;14:713–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh PK, Weber A, Hacker G. The established and the predicted roles of dynein light chain in the regulation of mitochondrial apoptosis. Cell Cycle. 2018;17:1037–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh PK, Roukounakis A, Weber A, Das KK, Sohm B, Villunger A, et al. Dynein light chain binding determines complex formation and posttranslational stability of the Bcl-2 family members Bmf and Bim. Cell Death Differ. 2020;27:434–50.

Article  CAS  PubMed  Google Scholar 

Barbar E. Dynein light chain LC8 is a dimerization hub essential in diverse protein networks. Biochemistry. 2008;47:503–8.

Article  CAS  PubMed  Google Scholar 

King SM. Dynein-independent functions of DYNLL1/LC8: redox state sensing and transcriptional control. Sci Signal. 2008;1:e51.

Article  Google Scholar 

Wong DM, Li L, Jurado S, King A, Bamford R, Wall M, et al. The transcription factor ASCIZ and its target DYNLL1 are essential for the development and expansion of MYC-driven B cell lymphoma. Cell Rep. 2016;14:1488–99.

Article  CAS  PubMed  Google Scholar 

Rayala SK, den Hollander P, Balasenthil S, Yang Z, Broaddus RR, Kumar R. Functional regulation of oestrogen receptor pathway by the dynein light chain 1. EMBO Rep. 2005;6:538–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He YJ, Meghani K, Caron MC, Yang C, Ronato DA, Bian J, et al. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature. 2018;563:522–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Becker JR, Cuella-Martin R, Barazas M, Liu R, Oliveira C, Oliver AW, et al. The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity. Nat Commun. 2018;9:5406.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berkel C, Cacan E. DYNLL1 is hypomethylated and upregulated in a tumor stage- and grade-dependent manner and associated with increased mortality in hepatocellular carcinoma. Exp Mol Pathol. 2020;117:104567.

Article  CAS  PubMed  Google Scholar 

Zhang RY, Liu ZK, Wei D, Yong YL, Lin P, Li H, et al. UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development. Signal Transduct Target Ther. 2021;6:64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ingham M, Schwartz GK. Cell-cycle therapeutics come of age. J Clin Oncol. 2017;35:2949–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahata S, Yu Y, Stillman DJ. The E2F functional analogue SBF recruits the Rpd3(L) HDAC, via Whi5 and Stb1, and the FACT chromatin reorganizer, to yeast G1 cyclin promoters. EMBO J. 2009;28:3378–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K, et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology. 2003;37:534–43.

Article  CAS  PubMed  Google Scholar 

Ohashi R, Gao C, Miyazaki M, Hamazaki K, Tsuji T, Inoue Y, et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 2001;21:657–62.

CAS  PubMed  Google Scholar 

Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, et al. CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol. 2018;8:608.

Article  PubMed  PubMed Central  Google Scholar 

Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408–24.

Article  CAS  PubMed  Google Scholar 

Sheng J, Kohno S, Okada N, Okahashi N, Teranishi K, Matsuda F, et al. Treatment of retinoblastoma 1-intact hepatocellular carcinoma with cyclin-dependent kinase 4/6 inhibitor combination therapy. Hepatology. 2021;74:1971–93.

Article  CAS  PubMed  Google Scholar 

Fang Y, Zhan Y, Xie Y, Du S, Chen Y, Zeng Z, et al. Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC. Hepatology. 2022;75:1386–401.

Article  CAS  PubMed  Google Scholar 

Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, et al. Disruption of tumor-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68:1653–66.

Article  CAS  PubMed  Google Scholar 

Chen CY, Ezzeddine N, Shyu AB, Messenger RNA. half-life measurements in mammalian cells. Methods Enzymol. 2008;448:335–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matthews HK, Bertoli C, de Bruin R. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23:74–88.

Article  CAS  PubMed  Google Scholar 

Rapali P, Radnai L, Süveges D, Harmat V, Tölgyesi F, Wahlgren WY, et al. Directed evolution reveals the binding motif preference of the LC8/DYNLL hub protein and predicts large numbers of novel binders in the human proteome. PLoS One. 2011;6:e18818.

Article  PubMed  PubMed Central  Google Scholar 

Rapali P, Szenes A, Radnai L, Bakos A, Pál G, Nyitray L. DYNLL/LC8: a light chain subunit of the dynein motor complex and beyond. FEBS J. 2011;278:2980–96.

Article  CAS  PubMed  Google Scholar 

Stallcup MR, Poulard C. Gene-specific actions of transcriptional coregulators facilitate physiological plasticity: evidence for a physiological coregulator code. Trends Biochem Sci. 2020;45:497–510.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D’Anca M, et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell. 2017;32:88–100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guan D, Altan-Bonnet N, Parrott AM, Arrigo CJ, Li Q, Khaleduzzaman M, et al. Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in mitotic control. Mol Cell Biol. 2008;28:4629–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barber GN. The NFAR’s (nuclear factors associated with dsRNA): evolutionarily conserved members of the dsRNA binding protein family. RNA Biol. 2009;6:35–39.

Article  CAS  PubMed  Google Scholar 

Li Y, Wang M, Yang M, Xiao Y, Jian Y, Shi D, et al. Nicotine-Induced ILF2 facilitates nuclear mRNA export of pluripotency factors to promote stemness and chemoresistance in human esophageal cancer. Cancer Res. 2021;81:3525–38.

Article  CAS  PubMed  Google Scholar 

Zhang X, Bustos MA, Gross R, Ramos RI, Takeshima TL, Mills GB, et al. Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma. Clin Transl Med. 2021;11:e608.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Che Y, Xuan B, Wu X, Li H. Serine hydroxymethyltransferase 2 (SHMT2) potentiates the aggressive process of oral squamous cell carcinoma by binding to interleukin enhancer-binding factor 2 (ILF2). Bioengineered. 2022;13:8785–97.

Article  CAS  PubMed  PubMed Central